Sernova Biotherapeutics Inc · TSX:SVA

Sernova Biotherapeutics — Sernova — Investor Presentation (August 2022)

34 slides from Sernova Biotherapeutics's investor presentation, August 2022

  1. Slide 1: Advancing regenerative therapeutics to develop 'functional cures'

    Slide 1: Advancing regenerative therapeutics to develop 'functional cures'

    Advancing regenerative therapeutics to develop ‘functional cures’ August, 2022 Corporate Presentation 1

  2. Slide 2: Forward looking statements

    Slide 2: Forward looking statements

    Forward looking statements This presentation contains forward-looking statements within the meaning of applicable Canadian securities laws. Forward-looking statements in this presentation are statements that are not historical facts and are generally, but not always, identified by the words “expects

  3. Slide 3: Investment Highlights

    Slide 3: Investment Highlights

    Investment Highlights Proprietary Cell • Proprietary implantable device containing therapeutic cells in an organ-like environment Pouch System™ • Once implanted, is naturally vascularized allowing self-sustaining cell survival for years • Licensed program in local immuno-protection technology abroga

  4. Slide 4: Sernova Executive Team and Board of Directors

    Slide 4: Sernova Executive Team and Board of Directors

    SERNOVA Executive TEAM Dr. Philip M. TOLEIKIS Frank SHANNON David SWETLOW BA, MSc, PhD Vice President Clinical CPA, CA CEO, President, Director Development and Chief Financial Officer Regulatory Affairs Board of Directors Frank HOLLER Jeffrey BACHA Deborah BROWN James PARSONS Dr. Mohammad Dr. Philip

  5. Slide 5: Sernova's Solution to Integrated Regenerative Medicine

    Slide 5: Sernova's Solution to Integrated Regenerative Medicine

    Sernova’s Solution to Integrated Regenerative Medicine • Proprietary implantable medical device • Provides vascularized environment for • 1st generation utilizes human therapeutic cells to survive donor cells for long periods of time – • 2nd generation off-the-shelf creating an organ-like stem cell

  6. Slide 6: Cell Pouch Containing Therapeutic Cells

    Slide 6: Cell Pouch Containing Therapeutic Cells

    Cell Pouch Containing Therapeutic Cells Biologically Compatible Delivery – Allows Natural Vascularization • Proprietary Cell Pouch placed • Therapeutic cells transplanted • Therapeutic cells responsive deep under the skin into the vascularized tissue to endogenous regulation chambers • Prepares an o

  7. Slide 7: Cell Pouch - Overcoming Limitations of Predecessors

    Slide 7: Cell Pouch - Overcoming Limitations of Predecessors

    Cell Pouch - Overcoming Limitations of Predecessors An effective organ-like environment Human donor cells Tissue Vascularizes Stem cell-derived islet cells No Fibrosis Sernova Scalable Cell Pouch Natural cell environment Biocompatible Cell engraftment 7

  8. Slide 8: Pipeline – Life Cycle Iterations and Multiple Indications

    Slide 8: Pipeline – Life Cycle Iterations and Multiple Indications

    Pipeline – Life Cycle Iterations and Multiple Indications Therapeutic Product Candidate Cell Source Immune Protection Indication Discovery Pre-Clinical Phase 1/2 Phase 3 BLA Human donor Immunosuppressives islet cells Type 1 Diabetes Human donor Local immune Cell Pouch System islet cells protection I

  9. Slide 9: Cell Pouch System For Type 1 Diabetes

    Slide 9: Cell Pouch System For Type 1 Diabetes

    Cell Pouch System For Type 1 Diabetes

  10. Slide 10: Diabetes: Global Disease = Global Market

    Slide 10: Diabetes: Global Disease = Global Market

    DIABETES GLOBAL DISEASE = GLOBAL MARKET Diabetes is one of the most prevalent diseases and most pervasive medical problems impacting society and quality of life today. 537 million people are affected worldwide with diabetes; another estimated 179 million people have it without knowing it. By 2045, p

  11. Slide 11: Lead Indication: Hypoglycemia Unawareness Among Type 1 Diabetic Patients

    Slide 11: Lead Indication: Hypoglycemia Unawareness Among Type 1 Diabetic Patients

    Lead Indication for Type 1 Diabetes Hypoglycemia Unawareness Among Type 1 Diabetic Patients Hypoglycemia Unawareness – most critical unmet need in T1D Affects 15% of T1D patients (~240k patients in the US) Clinically defined as a person’s inability to recognize the symptoms of low blood sugar before

  12. Slide 12: Phase 1/2 Study Design – Ongoing

    Slide 12: Phase 1/2 Study Design – Ongoing

    Phase 1/2 Study Design – Ongoing Patients with Type 1 Diabetes (T1D) and Hypoglycemia Unawareness Trial Overview • Open label, single-arm, single-center trial (n=7) • Insulin-dependent T1D patients with hypoglycemia unawareness Study • Cell Pouch implant followed by 2 sequential human donor islet tr

  13. Slide 13: Phase 1/2 Study – Current Patient Status and Design

    Slide 13: Phase 1/2 Study – Current Patient Status and Design

    Phase 1/2 Study – Current Patient Status and Design Primary Study Follow-up Baseline 1 MO +1 MO +6-12 MO +6-12 MO Ongoing Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 13

  14. Slide 14: Phase 1/2 Interim Results – ADA Presentation June 2022

    Slide 14: Phase 1/2 Interim Results – ADA Presentation June 2022

    Phase 1/2 Interim Results – ADA Presentation June 2022 • Surgical implantation of the Cell Pouch was found to be generally well tolerated with a favorable safety profile • All patients who had favorable immunosuppression achieved complete insulin independence • The first three transplanted patients

  15. Slide 15: Phase 1/2 Individual Patient Assessments – ADA June 2022

    Slide 15: Phase 1/2 Individual Patient Assessments – ADA June 2022

    Phase 1/2 Individual Patient Assessments – ADA June 2022 First Three Patients Patient 1 • Insulin independent at 2-year follow-up after Cell Pouch islet Tx and intraportal islet Tx • Positive for stimulated serum C-peptide after 1st Tx into Cell Pouch • HbA1c – 5.0 Patient 2 • Insulin independent at

  16. Slide 16: Sentinel Cell Pouch Histology Results - 90 Days Post-TX

    Slide 16: Sentinel Cell Pouch Histology Results - 90 Days Post-TX

    Sentinel Cell Pouch Histology Results - 90 Days Post-TX Sentinel Cell Pouch Sentinel Cell Pouch vWF+ DAPI Insulin + vWF + DAPI Insulin + vWF + DAPI Insulin +Somatostatin+ DAPI f f e e d 4x 20x d 4x 10x c c b b a a Insulin + Glucagon + DAPI Insulin +Somatostatin+ DAPI C-peptide + DAPI Insulin + CK-19

  17. Slide 17: Patient #1 – Impact Statement

    Slide 17: Patient #1 – Impact Statement

    Patient #1 – Impact Statement After completing the safety, tolerability and efficacy study of Sernova's Cell Pouch for clinical islet transplantation and as the first transplant candidate, I can easily state how absolutely wonderful life is to be free of always thinking of how to manage my diabetes.

  18. Slide 18: Evotec Partnership For Insulin-Producing Stem Cells

    Slide 18: Evotec Partnership For Insulin-Producing Stem Cells

    Evotec Partnership For Insulin-Producing Stem Cells

  19. Slide 19: Abundant Supply of Insulin-Producing Human iPSC's

    Slide 19: Abundant Supply of Insulin-Producing Human iPSC's

    Abundant Supply of Insulin-Producing Human iPSC’s • May 2022: acquired option for exclusive global license to Evotec’s Induced Pluripotent Stem Cell (iPSC)-based human beta cells for use with its Cell Pouch System or alone with other technologies • Access to unlimited supply of insulin-producing isl

  20. Slide 20: Strong Strategic Fit to Advance Potential 'Functional Cure' for Diabetes

    Slide 20: Strong Strategic Fit to Advance Potential 'Functional Cure' for Diabetes

    Strong Strategic Fit to Advance Potential ‘Functional Cure’ for Diabetes Partnership and licensing option agreement to enable a potential ‘functional cure’ for insulin-dependent diabetes without supply constraints Cell Pouch System™ • Implantable medical device / • iPSC-based islet-like immune prote

  21. Slide 21: E.iBETA Delivers Long-Term Efficacy in Preclinical Models

    Slide 21: E.iBETA Delivers Long-Term Efficacy in Preclinical Models

    E.iBETA Delivers Long-Term Efficacy in Preclinical Models High quality cell composition coupled with robust production process E.iBeta generated from a GMP iPSC line in bioreactor Long-term normalization of blood glucose in diabetic mice following E.iBeta transplantation Microscopy Histology C-PEPTI

  22. Slide 22: Cell Pouch System – Progress and 2022-2023 Goals

    Slide 22: Cell Pouch System – Progress and 2022-2023 Goals

    Cell Pouch System – Progress and 2022-2023 Goals Internal and External Advancement of Development and Commercialization Strategy Diabetes Program Next T1D Technology Therapeutic Product Development • Advance Sernova / Evotec Partnership E.iBETA iPSC-based islets in Cell Pouch as an off-the-shelf pro

  23. Slide 23: Conformal Coating For Cellular Immune Protection

    Slide 23: Conformal Coating For Cellular Immune Protection

    Conformal Coating For Cellular Immune Protection

  24. Slide 24: Conformal Coating Technology – for Immune Protection

    Slide 24: Conformal Coating Technology – for Immune Protection

    Conformal Coating Technology – for Immune Protection • ‘Shrink wrap’ properties • Thin biocompatible cross-linked allows volume of transplanted polymer hydrogel coating that cells into the Cell Pouch to be surrounds therapeutic cells Conformal Coating – unaffected University of Miami / Sernova Colla

  25. Slide 25: Conformal Coating Technology for Cellular Immune Protection

    Slide 25: Conformal Coating Technology for Cellular Immune Protection

    Conformal Coating Technology for Cellular Immune Protection University of Miami / Sernova Collaboration Preliminary Results Conformally Coated Rat Islet Isolated Rat Islets Conformal Coated Naked PEG, DAPI (nucleus) H&E staining of transplanted islets in Cell Pouch™ Naked islets in Cell Pouch™ Confo

  26. Slide 26: Conformal Coating + Cell Pouch: Summary of Key Findings

    Slide 26: Conformal Coating + Cell Pouch: Summary of Key Findings

    Conformal Coating + Cell Pouch: Summary of Key Findings Conformal Cell Pouch + Coating with Immuno-protection Summary Cells Cells Safety in non-human primates   • Volume of transplanted cells is unaffected • Distinct from other encapsulation methods, allows for Efficacy with donor islets in T1D pr

  27. Slide 27: Additional Pipeline Assets

    Slide 27: Additional Pipeline Assets

    Additional Pipeline Assets • Hypothyroidism • Hemophilia A

  28. Slide 28: Cell Pouch System for Hypothyroidism

    Slide 28: Cell Pouch System for Hypothyroidism

    Cell Pouch System for Hypothyroidism Therapeutic Benefits & Estimated Market ➔ 150,000 thyroidectomies performed annually just in the US Estimated Market ➔ $2.2B market opportunity Size ➔ Potential near-term revenue with patient own tissue ➔ Stem cell-derived technology for treatment of broad popula

  29. Slide 29: Validation of Cell Pouch System for Hypothyroidism

    Slide 29: Validation of Cell Pouch System for Hypothyroidism

    Validation of Cell Pouch System for Hypothyroidism 29

  30. Slide 30: Cell Pouch System Rare Disease Program – Hemophilia A

    Slide 30: Cell Pouch System Rare Disease Program – Hemophilia A

    Cell Pouch System Rare Disease Program – Hemophilia A Therapeutic Benefits & Estimated Market ➔ 20,000 patients across North America and EU Estimated Market ➔ $10B orphan indication Size ➔ First generation • AUTOGRAFT: Patient’s own blood outgrowth endothelial cells (BOEC) are isolated, expanded and

  31. Slide 31: Preclinical POC for Hemophilia A

    Slide 31: Preclinical POC for Hemophilia A

    Preclinical POC for Hemophilia A Preclinical Safety & Efficacy of Hemophilia Cell Therapy in the Cell Pouch Human factor VIII- corrected blood outgrowth endothelial cells (BOECs) were implanted within the Cell Pouch in a hemophilia A murine model Confirmed Release- Non-transplanted Cell Non-transpla

  32. Slide 32: Validation of Cell Pouch System for Hemophilia A

    Slide 32: Validation of Cell Pouch System for Hemophilia A

    Validation of Cell Pouch System for Hemophilia A 32

  33. Slide 33: Summary – Advancing Towards Multiple Near-Term Catalysts

    Slide 33: Summary – Advancing Towards Multiple Near-Term Catalysts

    Summary – Advancing Towards Multiple Near-Term Catalysts • Complete regenerative medicine package for insulin-dependent diabetes Proprietary Device • Advancing programs for hypothyroidism and hemophilia A to clinic • Cell Pouch System able to treat multiple human afflictions where the body is defici

  34. Slide 34: Head Office, Investor Relations, Business Development

    Slide 34: Head Office, Investor Relations, Business Development

    Business Development Investor Relations Dr. Philip Toleikis Head Office Christopher Barnes VP, Investor Relations 1.519.858.5184 700 Collip Circle, Ste 114 philip.toleikis@sernova.com 1.519.902.7923 London, ON, Canada N6G 4X8 christopher.barnes@sernova.com Tel: 1.877.299.4603 Tel: 1.519.858.5184 Cor

Source: Internet Archive copy of sernova.com

More decks from Sernova Biotherapeutics Inc

All 29 Sernova Biotherapeutics decks